Clinical Trial Evidence of Association between Antidopaminergic Medications and Clinical Measurements of Huntington’s Disease Progression Published in Neurology®

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)– #HD–Prilenia Therapeutics B.V. and Ferreri today announced the publication online, on October 22, 2026, of a new manuscript, in Neurology®, the medical journal of the American Academy of Neurology, presenting a post hoc analysis providing Phase 3 clinical trial evidence of the association between exposure to antidopaminergic medications (ADMs) and clinical outcome measures  in Huntington’s disease (HD) . The manuscript, “Ant